Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

VRE fecal colonization/infection in cancer patients

Bone Marrow Transplantation volume 39, pages 567–568 (2007)Cite this article

We read with interest the article by Dubberke et al.1 regarding their experience with vancomycin-resistant enterococcal bloodstream infections in a hematopoietic stem cell transplant (HSCT) unit. Experience at our institution, an National Cancer Institute designated Comprehensive Cancer center, is similar to theirs in some aspects, and different in other aspects. We screened 2115 patients for fecal colonization with vancomycin resistant enterococci (VRE), including 955 with hematologic malignancies (leukemia, myeloma, myelodysplastic syndromes), 653 HSCT recipients, and 507 patients with lymphoma.2 VRE were recovered from fecal smears of 56 patients with hematologic malignancies (5.9%), 32 HSCT recipients (4.7%) and 11 lymphoma patients (2.2%) for an overall frequency of colonization of 4.7%. Thirty-one episodes of VRE bacteremia occurred in these patients, with all but two episodes occurring in patients with VRE fecal colonization. Thus fecal colonization with VRE had a positive predictive value of 29.3% for the subsequent development of VRE bacteremias. Additionally, the negative predictive value of fecal smears was 99.9% in these high-risk patients. The species distribution of our VRE isolates was as follows: Enterococcus faceium – 77%; E. faecalis – 13%; and other species (E. avium, E. casseliflavus, E. durans, E. gallinarim, E. raffinosus) – 10%. Five of the 31 episodes of bacteremia (16%) were polymicrobial with enteric gram-negative bacilli being the predominant co-isolates. Several patients developed infection at other sites without developing bacteremia (Table 1). The urinary tract was the most common site followed by skin and skin structure infection, biliary tract infection, and one episode of meningitis. VRE were also isolated from respiratory samples (sputum; bronchoalveolar lavage (BAL)) of seven patients who did not meet the criteria for pneumonia and were considered to be colonized. The mortality directly attributable to VRE bacteremia was <7%. Eight patients of the 31 with VRE bacteremia (26%) developed and survived a subsequent episode of bacteremia over a 1-year follow-up period, providing further evidence of the low pathogenicity/virulence of these organisms.

Table 1 Distribution of infections caused by VRE in various subgroups of patients with cancer
Full size table

We also looked for VRE infection rates in our solid tumor patients over the same study period (Table 1). Fecal smears to detect VRE colonization are not routinely performed in these patients, consequently VRE colonization rates could not be determined. Nevertheless 10 episodes of VRE bacteremia occurred in 8538 patients (0.12%), and 42 episodes of infection (0.49%) occurred at other sites giving an overall infection rate of 0.61%, significantly lower than in patients with hematologic malignancies/HSCT recipients (P=<0.001). Patients with hematologic malignancies were 17.3 times more likely to get VRE bacteremia (95% confidence interval (95% CI): 8.0–37.3) and 3.7 times more likely to get VRE infection at other sites (95% CI: 2.1–6.5) than patients with solid tumors. Similarly HCST recipients were 11.9 times more likely to get VRE bacteremia (95% CI: 4.8–29.4), and 3.5 times more likely to get VRE infection at other sites (95% CI: 1.8–6.8) than solid tumor patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dubberke ER, Hollands JM, Georgantopoulos P, Augustin K, DiPersio JF, Mundy LM et al. Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant 2006; 38: 813–819.

    Article  CAS  Google Scholar 

  2. Matar MJ, Tarrand J, Raad I, Rolston KVI . Colonization and infections with vancomycin-resistant enterococcus among patients with cancer. Am J Infect Control 2006; 34: 534–536.

    Article  Google Scholar 

  3. Hachem R, Graviss L, Hanna H, Arbuckle R, Dvorak T, Hackett B et al. Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak among patients with hematologic malignancy. Infect Control Hosp Epidemiol 2004; 25: 391–394.

    Article  Google Scholar 

  4. Raad II, Hanna HA, Hachem RY, Dvorak T, Arbuckle RB, Chaiban G et al. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob Agents Chemother 2004; 48: 3583–3585.

    Article  CAS  Google Scholar 

  5. Prince R, Coyle E, Rolston K, Kapadia M, Kaur A, McCauley S . In vitro activity of daptomycin and linezolid against vancomycin-resistant gram-positive pathogens from cancer patients. (Abstract). 17th European Congress of Clinical Microbiology and Infectious Diseases (Munich), 2007.

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    K V I Rolston & Y Jiang

  2. Department of Infectious Diseases, Infection Control Notre Dame de Secours Hospital, Jbeil, Lebanon

    M Matar

Authors
  1. K V I Rolston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Matar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K V I Rolston.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rolston, K., Jiang, Y. & Matar, M. VRE fecal colonization/infection in cancer patients. Bone Marrow Transplant 39, 567–568 (2007). https://doi.org/10.1038/sj.bmt.1705639

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705639

This article is cited by

Search

Advanced search

Quick links